Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Cytotoxic Edema: Pathophysiology01:21

Cytotoxic Edema: Pathophysiology

Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Robot-assisted Kidney Transplantation: The 8-year European experience" [Eur. Urol. 87(4) (2025) 468-475].

European urology·2026
Same author

Years of Life Lost in Incidental Prostate Cancer.

The Prostate·2026
Same author

PROTEUS Trial the Day After: Practice Changing or Premature Escalation?

European urology oncology·2026
Same author

Real-World Effectiveness of Baricitinib in Rheumatoid Arthritis: Significant Reduction of Disease Activity Independent of Age in a Multicentre Retrospective Cohort Study.

Mediterranean journal of rheumatology·2026
Same author

Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.

Journal of psoriasis and psoriatic arthritis·2026
Same author

Years of life lost from metastatic prostate cancer according to household income.

World journal of urology·2026

Related Experiment Videos

Cyclophosphamide treatment improves microvessel damage in systemic sclerosis.

Paola Caramaschi1, Alessandro Volpe, Sara Pieropan

  • 1Dipartimento di Medicina Clinica e Sperimentale, Università di Verona, Policlinico G.B. Rossi, Piazzale Scuro, 37134 Verona, Italy. paola.caramaschi@azosp.vr.it

Clinical Rheumatology
|December 5, 2008
PubMed
Summary

Cyclophosphamide therapy significantly improved nailfold videocapillaroscopy findings in systemic sclerosis patients, indicating reduced microvascular damage. This treatment showed a protective effect against worsening capillary abnormalities.

Related Experiment Videos

Area of Science:

  • Rheumatology
  • Dermatology
  • Microcirculation Research

Background:

  • Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by microvascular damage.
  • Nailfold videocapillaroscopy (NVc) is a non-invasive method to assess microvascular abnormalities in SSc.
  • Iloprost is a common treatment for SSc, but its effect on microvascular changes needs further evaluation.

Purpose of the Study:

  • To evaluate changes in nailfold videocapillaroscopy (NVc) patterns in systemic sclerosis (SSc) patients treated with iloprost.
  • To identify associations between NVc changes and clinical, serologic, and pharmacological variables.
  • To assess the efficacy of specific therapies, particularly cyclophosphamide, on SSc-related microvascular damage.

Main Methods:

  • Prospective study involving 49 patients with systemic sclerosis (SSc).
  • Two nailfold videocapillaroscopy (NVc) examinations were conducted 3 years apart by a blinded operator.
  • Patients were treated regularly with iloprost; specific therapies like cyclophosphamide, methotrexate, and azathioprine were analyzed.

Main Results:

  • Six patients (12.2%) showed improvement in NVc patterns, transitioning from active to early stages.
  • Five of these six patients (83.3%) had received cyclophosphamide therapy.
  • Cyclophosphamide administration was significantly associated with NVc amelioration (p<0.001) and inversely correlated with disease progression (p=0.02).

Conclusions:

  • Cyclophosphamide treatment demonstrated significant efficacy in improving microvascular damage in systemic sclerosis (SSc) as observed via nailfold videocapillaroscopy (NVc).
  • The absence of worsening NVc findings in patients treated with cyclophosphamide suggests a protective effect on microvasculature.
  • Further research should explore the long-term impact of cyclophosphamide on SSc microvascular complications.